OverviewSuggest Edit

Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets. The Company applies its antibody capabilities to create immunotherapies for cancer patients of all ages. Y-mAbs Therapeutics' mission is to develop better and safer antibody based pediatric oncology products addressing clear unmet medical needs.

TypePublic
Founded2014
HQNew York, NY, US
Websiteymabs.com

Latest Updates

Employees (est.) (Dec 2018)32(+40%)
Revenue (FY, 2020)$20.8 M
Share Price (Sept 2021)$33.1
Cybersecurity ratingBMore

Key People/Management at Y-mAbs Therapeutics

Thomas Gad

Thomas Gad

Chairman

Y-mAbs Therapeutics Office Locations

Y-mAbs Therapeutics has offices in New York, Nutley and Hørsholm
New York, NY, US (HQ)
230 Park Ave #3350
Nutley, NJ, US
111 Ideation Way basement floor, room c
Nutley, NJ, US
340 Kingsland St building 102
Hørsholm, DK
Agern Alle 11
Show all (4)

Y-mAbs Therapeutics Financials and Metrics

Y-mAbs Therapeutics Revenue

Y-mAbs Therapeutics's revenue was reported to be $20.8 m in FY, 2020
USD

Net income (Q1, 2021)

33.4m

EBIT (Q1, 2021)

(28.3m)

Market capitalization (2-Sept-2021)

1.4b

Closing stock price (2-Sept-2021)

33.1

Cash (31-Mar-2021)

252.3m

EV

1.2b
Y-mAbs Therapeutics's current market capitalization is $1.4 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

20.8m

General and administrative expense

3.2m4.9m9.0m19.5m44.8m

R&D expense

13.9m14.3m34.3m63.5m

Operating expense total

17.0m19.2m43.2m83.0m44.8m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cost of goods sold

93.0k

General and administrative expense

766.0k2.7m3.7m4.1m4.7m8.1m10.4m11.6m12.0m

R&D expense

3.1m8.7m12.5m14.5m19.7m18.6m30.1m21.0m21.6m

Operating expense total

3.8m11.4m16.3m18.6m24.4m26.7m40.5m32.6m33.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

16.9m90.5m147.8m207.1m114.6m

Prepaid Expenses

3.7m

Current Assets

17.3m91.4m151.5m212.0m122.4m

PP&E

205.0k2.1m1.8m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

70.2m163.3m134.2m120.2m98.2m185.8m158.1m131.3m252.3m

Accounts Receivable

6.0m

Prepaid Expenses

2.8m3.0m1.4m

Inventories

1.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(17.1m)(19.2m)(43.3m)(81.0m)(119.3m)

Depreciation and Amortization

29.0k166.0k396.0k

Accounts Payable

836.0k2.4m1.3m2.6m852.0k

Cash From Operating Activities

(11.2m)(15.9m)(41.2m)(73.5m)(91.2m)
Quarterly
USDQ2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(6.1m)(9.9m)(17.8m)(29.2m)(15.9m)(34.0m)(57.9m)(26.2m)(66.6m)(99.4m)33.4m

Depreciation and Amortization

19.0k39.0k87.0k86.0k186.0k279.0k130.0k

Inventories

(1.0m)

Accounts Payable

(636.0k)317.0k(368.0k)1.7m(134.0k)3.0m1.0m1.7m1.3m1.8m(2.8m)
USDFY, 2016

Financial Leverage

1.4 x
Show all financial metrics

Y-mAbs Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Y-mAbs Therapeutics Online and Social Media Presence

Embed Graph

Y-mAbs Therapeutics News and Updates

Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced …

Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announc…

Y-mAbs Therapeutics To Present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas

NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced toda…

Y-mAbs Therapeutics To Present At Cowen’s 39th Annual Health Care Conference

NEW YORK, March 08, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced tod…

Y-mAbs Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference

NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced toda…
Show more

Y-mAbs Therapeutics Blogs

Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China Content Import Mon, 09/13/2021 - 09:02 Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China Sep 13, 2021 This release is a backfill from a News …

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments Content Import Thu, 08/05/2021 - 16:04 Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments Aug 05, 2021 This release is a backfill from…

Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021

Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021 Content Import Thu, 07/29/2021 - 16:09 Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021 Jul 29, 2021 This release is a bac…

Associate Director / Director Marketing EU

The company is currently building out the commercial organization in preparation for further launches in the US and Europe. This position will play a central role in preparing for the launch of Omburtamab and Naxitamab in Europe. The post Associate Director / Director Marketing EU appeared first on …

DK Associate Director, PV QA

Join a visionary company on their exciting journey and make your mark on the newly established PV QA function. The post DK Associate Director, PV QA appeared first on Y-mAbs Therapeutics, Inc..

DK – Project Assistant, Translational medicine

Are you ready to join an expanding an innovative biopharmaceutical company and play a part in our non-clinical development efforts? We are looking for you. The post DK – Project Assistant, Translational medicine appeared first on Y-mAbs Therapeutics, Inc..
Show more

Y-mAbs Therapeutics Frequently Asked Questions

  • When was Y-mAbs Therapeutics founded?

    Y-mAbs Therapeutics was founded in 2014.

  • Who are Y-mAbs Therapeutics key executives?

    Y-mAbs Therapeutics's key executives are Thomas Gad.

  • How many employees does Y-mAbs Therapeutics have?

    Y-mAbs Therapeutics has 32 employees.

  • What is Y-mAbs Therapeutics revenue?

    Latest Y-mAbs Therapeutics annual revenue is $20.8 m.

  • What is Y-mAbs Therapeutics revenue per employee?

    Latest Y-mAbs Therapeutics revenue per employee is $650 k.

  • Who are Y-mAbs Therapeutics competitors?

    Competitors of Y-mAbs Therapeutics include WuXi AppTec, Prevail Therapeutics and Nordic Nanovector.

  • Where is Y-mAbs Therapeutics headquarters?

    Y-mAbs Therapeutics headquarters is located at 230 Park Ave #3350, New York.

  • Where are Y-mAbs Therapeutics offices?

    Y-mAbs Therapeutics has offices in New York, Nutley and Hørsholm.

  • How many offices does Y-mAbs Therapeutics have?

    Y-mAbs Therapeutics has 4 offices.